Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for improved ...

—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...

Biomarker testing has become “increasingly critical” in the care of non-small cell lung cancer.A new investigation into testing rates proved “reassuring” to Kenneth L. Kehl, MD, MPH, assistant ...

Please provide your email address to receive an email when new articles are posted on . NCCN recommends osimertinib plus chemotherapy or lazertinib plus amivantamab-vmjw as first-line options for EGFR ...

—A team of researchers in Tokyo recently took on the challenge of attempting to determine whether comprehensive genomic profiling has clinical utility in a large cohort of patients with non-small cell ...

The US Food and Drug Administration (FDA) has granted approval for Thermo Fisher Scientific's Oncomine Dx Target Test as a treatment for non-small cell lung cancer (NSCLC). The test serves as a ...

The definition of comprehensive non-small cell lung cancer (NSCLC) testing is rapidly evolving with new biomarkers and therapies, according to Julia Rotow, MD, creating added challenges for community ...

An expert discusses the evolution of ROS1 testing in non-small cell lung cancer, highlighting the shift from FISH-based methods to comprehensive next-generation sequencing of both tissue and plasma, ...

Validated companion diagnostic offers rapid results and supports eligible patient selection for newly approved targeted therapy FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NEO), a leading ...